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Background: The bone scan ﬂare phenomenon is deﬁned as worsening 
of bone lesions with subsequent improvement during effective cancer 
treatment. Due to dramatic and prompt response to epidermal growth 
factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in a subgroup of 
lung cancer patients, ﬂare phenomenon may be observed. 
Materials and Methods: Between July 2003 and October 2005, we 
retrospectively examined the radiographic and scintigraphic images of 
lung cancer patients who had previous geﬁtinib treatment. Those who 
had pretreatment and two posttreatment bone scan examinations were 
included in this study. New lesions or increased intensity observed on 
the ﬁrst follow-up bone scan with improvement on the second one dur-
ing geﬁtinib treatment was deﬁned as positive for ﬂare phenomenon. 
The results were correlated with clinical disease status.
Results: There were 33 non-small-cell lung cancer (NSCLC) patients 
included. Seven (21.2%) of them showed bone scan ﬂare phenomenon. 
Five of them were adenocarcinoma, and two were unspeciﬁed NSCLC. 
All these cases demonstrated partial response after treatment, and the 
ﬂare phenomena were detected between 29 ~ 77 days (median: 34 
days) after treatment. 
Conclusions: We presented the ﬁrst report concerning bone scan ﬂare 
in EGFR-TKI-treated NSCLC. Accordingly, facing a bone scan which 
shows progressive ﬁndings in the early treatment stage in an otherwise 
clinically improving patient, we should always keep this phenomenon 
in mind. This phenomenon may become more obvious in the era of 
targeted therapy.
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Clinical predictor of response to gefitinib in Thai patients with non-
small cell lung cancer.
Charoentum, Chaiyut Thongprasert, Sumitra Chewasakulyong, 
Busayamas Munprakarn, Suthirak 
Chiang Mai University, Chiang Mai, Thailand
Background: In previous clinical trials of geﬁtinib (i.e. IDEAL and 
ISEL), predictors of response include female sex, absence of smok-
ing history and adenocarcinoma histology. The objective of this study 
was to validate these clinical characteristics as predictor of geﬁtinib 
response in Thai patient populations. 
Methods: Patients with non-small cell lung cancer who has no smok-
ing history and adenocarcinoma histology receiving therapy with 
geﬁtinib at Maharaj Nakorn Chiang Mai hospital were retrospectively 
analyzed.
Results: From July 2005 to December 2007, 15 patients were identi-
ﬁed. Geﬁtinib was the 1st-, 2nd- and 3rd-line therapy for metastatic 
NSCLC in 1, 9 and 5 patients, respectively. There were 3 males and 12 
females with a median age of 57(range 46-75) and median ECOG PS of 
1 (range 1-3). There were 8 PR, 1 NE, 4 SD and 2 PD (overall response 
rate of 57%). Disease controlled rate (PR+SD) was achieved in 80% of 
patients. Symptoms improvement was observed in 13 patients (87%). 
All 3 male patients had symptoms improvement after therapy, 2 pa-
tients had partial response while the other had symptom improvement 
without measurable disease. 4 patients had died with survival time 
after treatment with geﬁtinib ranging from 10.5-15 months. 5 patients 
are currently receiving therapy with geﬁtinib. Therapy was generally 
well tolerated. Treatment interruption from side effects occurred in 3 
patients (1 from grade 2 skin rash, 1 from conjunctivitis, 1 from severe 
paronychia). Median duration of response and survival has not reached.
Conclusion: This result indicates that never-smoking status and 
adenocarcinoma histology are reliable clinical predictors of favorable 
response to geﬁtinib in Thai patients with NSCLC. 
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Predictive and prognostic role of mutations in epidermal growth 
factor receptor and KRAS in gefitinib treated non-small-cell lung 
cancer from China
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Background: Targeted therapy has shown much promise for patients 
with NSCLC. Results of IDEAL1 and IDEAL2 suggested that ﬁnding 
reliable biomarkers to predict response of patients with NSCLC to 
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor 
geﬁtinib was mandatory. To assess the relationship between geﬁtinib 
response in NSCLC patients from China and mutations in EGFR and 
K-ras, we examined mutational status in EGFR and K-ras in 30 geﬁ-
tinib treated NSCLC patients. 
Methods: DNA extracted from parafﬁn-embedded tumor samples from 
eligible patients were analyzed for EGFR and K-ras mutations using 
the nested PCR and direct sequencing. All types of mutations identiﬁed 
by PCR products sequencing were cloned and sequenced. 
Results: Among 30 patients, 10 harbored EGFR mutations and 4 har-
bored K-ras mutations. According to changes of amino acid sequence 
induced by mutations, mutations observed in EGFR consisted of six 
types: in-frame deletions in exon 19 (E746-A750), stop mutation in 
